These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34060012)

  • 1. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.
    Puig L; Bakulev AL; Kokhan MM; Samtsov AV; Khairutdinov VR; Morozova MA; Zolkin NA; Kuryshev IV; Petrov AN; Artemeva AV; Zinkina-Orikhan AV
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1319-1332. PubMed ID: 34060012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
    Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
    Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
    Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
    Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
    Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
    Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
    Nakagawa H; Niiro H; Ootaki K;
    J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
    Seo SJ; Shin BS; Lee JH; Jeong H
    J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D; Vender R; de Rie MA; Conrad C; Pariser DM; Strober B; Vanvoorden V; Wang M; Madden C; de Cuyper D; Kimball AB
    Br J Dermatol; 2023 Jan; 188(1):22-31. PubMed ID: 36689515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
    Yu C; Geng S; Yang B; Deng Y; Li F; Kang X; Bi M; Zhang F; Zhao Y; Pan W; Tian Z; Xu J; Zhang Z; Yu N; Duan X; Guo S; Sun Q; Li W; Tao J; Liu Z; Yin Y; Wang G
    Chin Med J (Engl); 2024 May; 137(10):1190-1198. PubMed ID: 38192233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.